Tomorrow Unveiled: Your Weekly Tech Briefing
How a Personalized Melanoma Vaccine Cuts Recurrence Risk by 42%
· 12 mnt
Catatan episode
Phase 3 trial: A personalized mRNA vaccine, individually designed from each patient's tumor mutations, reduced melanoma recurrence risk by 42%. How...
Watch on YouTube: https://www.youtube.com/watch?v=do12NINkwJU
